Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort.
Journal
Nature cancer
ISSN: 2662-1347
Titre abrégé: Nat Cancer
Pays: England
ID NLM: 101761119
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
27
05
2020
accepted:
24
08
2020
entrez:
5
2
2022
pubmed:
1
10
2020
medline:
15
2
2022
Statut:
ppublish
Résumé
Patients with cancer are presumed to be at increased risk of severe COVID-19 outcomes due to underlying malignancy and treatment-induced immunosuppression. Of the first 178 patients managed for COVID-19 at the Gustave Roussy Cancer Centre, 125 (70.2%) were hospitalized, 47 (26.4%) developed clinical worsening and 31 (17.4%) died. An age of over 70 years, smoking status, metastatic disease, cytotoxic chemotherapy and an Eastern Cooperative Oncology Group score of ≥2 at the last visit were the strongest determinants of increased risk of death. In multivariable analysis, the Eastern Cooperative Oncology Group score remained the only predictor of death. In contrast, immunotherapy, hormone therapy and targeted therapy did not increase clinical worsening or death risk. Biomarker studies found that C-reactive protein and lactate dehydrogenase levels were significantly associated with an increased risk of clinical worsening, while C-reactive protein and D-dimer levels were associated with an increased risk of death. COVID-19 management impacted the oncological treatment strategy, inducing a median 20 d delay in 41% of patients and adaptation of the therapeutic strategy in 30% of patients.
Identifiants
pubmed: 35121871
doi: 10.1038/s43018-020-00120-5
pii: 10.1038/s43018-020-00120-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
965-975Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020. The Author(s), under exclusive licence to Springer Nature America, Inc.
Références
Liang, W. et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 21, 335–337 (2020).
doi: 10.1016/S1470-2045(20)30096-6
Guan, W.-J. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 382, 1708–1720 (2020).
doi: 10.1056/NEJMoa2002032
Grasselli, G. et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. J. Am. Med. Assoc. https://doi.org/10.1001/jama.2020.5394 (2020).
Simpson, S. et al. Radiological society of North America expert consensus statement on reporting chest CT Findings related to COVID-19. Endorsed by the society of thoracic radiology, the American College of Radiology, and RSNA. J. Thorac. Imag. https://doi.org/10.1097/RTI.0000000000000524 (2020).
Richardson, S. et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. J. Am. Med. Assoc. https://doi.org/10.1001/jama.2020.6775 (2020).
Williamson, E. J. et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature https://doi.org/10.1038/s41586-020-2521-4 (2020).
Miyashita, H. et al. Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. https://doi.org/10.1016/j.annonc.2020.04.006 (2020).
Dai, M. et al. Patients with cancer appear more vulnerable to SARS-COV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-20-0422 (2020).
Kuderer, N. M. et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet 395, 1907–1918 (2020).
doi: 10.1016/S0140-6736(20)31187-9
Garassino, M. C. et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 21, 914–922 (2020).
doi: 10.1016/S1470-2045(20)30314-4
Mehta, V. et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-20-0516 (2020).
Luo, J. et al. Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-20-0596 (2020).
Lee, L. Y. W. et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet 395, 1919–1926 (2020).
doi: 10.1016/S0140-6736(20)31173-9
Zhang, J.-J. et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy https://doi.org/10.1111/all.14238 (2020).
Tan, L. et al. Validation of predictors of disease severity and outcomes in COVID-19 patients: a descriptive and retrospective study. Med. https://doi.org/10.1016/j.medj.2020.05.002 (2020).
Ray-Coquard, I. et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 69, 5383–5391 (2009).
doi: 10.1158/0008-5472.CAN-08-3845
Wen, W. et al. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. Cell Discov. 6, 31 (2020).
doi: 10.1038/s41421-020-0168-9
Zhou, Y. et al. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. Natl Sci. Rev. https://doi.org/10.1093/nsr/nwaa041 (2020).
Merad, M. & Martin, J. C. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat. Rev. Immunol. https://doi.org/10.1038/s41577-020-0331-4 (2020).
Dinmohamed, A. G. et al. Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands. Lancet Oncol. https://doi.org/10.1016/S1470-2045(20)30265-5 (2020).
Richards, M., Anderson, M., Carter, P., Ebert, B. L. & Mossialos, E. The impact of the COVID-19 pandemic on cancer care. Nat. Cancer https://doi.org/10.1038/s43018-020-0074-y (2020).
Van de Haar, J. et al. Caring for patients with cancer in the COVID-19 era. Nat. Med. 26, 665–671 (2020).
doi: 10.1038/s41591-020-0874-8
Scotté, F. et al. A patient reported outcome platform, a useful tool to improve monitoring and effective management of COVID-19-positive patients with cancer. Eur. J. Cancer Oxf. Engl. 1990 132, 1–4 (2020).
COVID-19 Therapeutic Trial Synopsis (World Health Organization, 2020); https://www.who.int/publications-detail/covid-19-therapeutic-trial-synopsis
Harris, P. A. et al. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inform. 42, 377–381 (2009).
doi: 10.1016/j.jbi.2008.08.010
Harris, P. A. et al. The REDCap consortium: building an international community of software platform partners. J. Biomed. Inform. 95, 103208 (2019).
doi: 10.1016/j.jbi.2019.103208
Corman, V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 25, 2000045 (2020).
Cao, B. et al. A trial of lopinavir–ritonavir in adults hospitalized with severe COVID-19. N. Engl. J. Med. 382, 1787–1799 (2020).
doi: 10.1056/NEJMoa2001282
Wang, Y. et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395, 1569–1578 (2020).
doi: 10.1016/S0140-6736(20)31022-9
Michot, J.-M. et al. Tocilizumab, an anti-IL-6 receptor antibody, to treat Covid-19-related respiratory failure: a case report. Ann. Oncol. https://doi.org/10.1016/j.annonc.2020.03.300 (2020).
Gautret, P. et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents https://doi.org/10.1016/j.ijantimicag.2020.105949 (2020).
Million, M. et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. Travel Med. Infect. Dis. https://doi.org/10.1016/j.tmaid.2020.101738 (2020).
Russell, C. D., Millar, J. E. & Baillie, J. K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 395, 473–475 (2020).
doi: 10.1016/S0140-6736(20)30317-2
Vuagnat, P. et al. COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area. Breast Cancer Res. 22, 55 (2020).
doi: 10.1186/s13058-020-01293-8